

pCODR Clinician Conflict of Interest Declarations

Please Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician: Mary Lynn Savoie

> Rituximab in combination with standard chemotherapy for Philadelphia chromosome negative, CD20 antigen positive, B cell precursor acute lymphoblastic leukemia in

> > i

Name of drug and indication under review: adults

Conflict of Interest Declarations

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities e.g., educational or research grants, honoraria, gifts, and salary;
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

Sec	ction A:	Payment Received	1		
1.	Have you received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review?				
	□ ⊠ If no,	Yes No please go to Section	В		
2.	What form of payment did you receive? (Check all that apply.)				
		Advisory role (e.g., advisory boards, HTA submission advice)		Program or Operating Funding (e.g., website)	
		Conference attendance		Research/educational grants	
		Royalties		Travel grants	
		Gifts		Sponsorship of Events	
		Honoraria		Other, please specify:	

	Please provide the names of companies and organizations and the amounts of the payments in the box below.					
Section B: Hol	ldings or Other Ir	terests				
mutual funds)		session of stocks or options of more than \$10,000 (excluding that may have a direct or indirect interest in the drug under table below.				
Section C: Aff	iliations, person	al or commercial relationships				
manufacturer associated cor	(including such ma porations) or othe	rcial relationships either with a drug or health technology anufacturer's parent corporation, subsidiaries, affiliates and r interest groups? If yes, please provide the names of the d outline the nature of these relationships in the table below.				
		osed all relevant information with respect to any matter involving eal, potential or perceived conflict of interest situation.				
Date: 2017/02/23	Name: Mary Lynn Savoie	Taros				
		Signature:				